Hepcidin is a liver-synthesized hormone that plays a central role in the regulation of systemic iron homeostasis. To produce a new tool for its functional properties the cDNA coding for camel hepcidin-25 was cloned at the 5'end of human FTH sequence into the pASK-IBA43plus vector for expression in Escherichia coli. The recombinant fusion hepcidin-ferritin-H subunit was isolated as an insoluble iron-containing protein. When alone it did not refold in a 24-mer ferritin molecule, but it did when renatured together with H-or L-ferritin chains. We obtained stable ferritin shells exposing about 4 hepcidin peptides per 24-mer shell. The molecules were then reduced and re-oxidized in a controlled manner to allow the formation of the proper hepcidin disulfide bridges. The functionality of the exposed hepcidin was confirmed by its ability to specifically bind the mouse macrophage cell line J774 that express ferroportin and to promote ferroportin degradation. This chimeric protein may be useful for studying the hepcidin-ferroportin interaction in cells and also as drug-delivery agent.
Introduction
There has been significant progress in identifying the molecules controlling iron homeostasis and their mode of action (Recalcati et al., 2010; Pantopoulos et al., 2012) . Hepcidin is the key iron regulatory hormone (Ganz, 2003) . It is a 25 amino acid peptide belonging to the β-defensin family, isolated for the first time from plasma and human urine (Krause et al., 2000; Park et al., 2001) , and consists of a cysteine-rich cationic peptide engaged with four disulfide bridges which plays a major role in innate immunity and iron homeostasis (Falzacappa and Muckenthaler, 2005; Houamel et al., 2016) . It is induced by iron abundance and inflammation and is suppressed by iron deficiency and hypoxia. Recently it has been reported that circulating hepcidin-25 is reduced by endogenous estrogen in humans (Lehtihet et al., 2016) . Hepcidin binds and inhibits ferroportin1, the only cellular iron exporter (Ramey et al., 2010) and thus, high hepcidin reduces while low hepcidin increases systemic iron availability (Nemeth and Ganz, 2006) . Furthermore, modulation of this peptide can offer promising clinical applications to treat iron deregulation (Blanchette et al., 2016) . Hepcidin acts via its N-terminal domain of 7-9 amino acids, including a thiol cysteine, that is the minimal structure retaining hepcidin activity (Preza et al., 2011) . The 3D structure of human hepcidin is known (Jordan et al., 2009) . Recombinant human and mouse hepcidins were expressed in Escherichia coli in fusion with a thioredoxin and treated by two sequential proteolytic enzymes to obtain functional hepcidin, in low yield <10% (Gagliardo et al., 2008) . A similar procedure was used to clone and express camel hepcidin, which showed to be functionally equivalent to the human one in binding and inhibiting ferroportin, using mouse monocyte-macrophage cell line J774 treated with Fe-nitrilotriacetate (Boumaiza et al., 2015) . Here we planned to fuse camel hepcidin with human ferritin H-chain to obtain a chimeric camel hepcidinhuman ferritin H-chain subunit (HepcH).
Ferritin is a spherical protein complex formed by 24 subunits of H-and L-chains which stores up to 4000 iron atoms as an oxidized mineral core (Arosio et al., 2009) . It is probably the most used protein in bionanotechnology. This is due to its well-known structural features, high stability, capability to mineralize metals in its cavity, self-assembly and possibility to redesign its interior and exterior by protein engineering (Martsev et al., 1998; Kanekiyo et al., 2013; Jutz et al., 2015) . It has been used to encapsulate molecules, for the synthesis of inorganic cores, for functional nanostructured composite material, for magnetic nanoparticles with MRI applications and for carrying various epitopes (Cai et al., 2015) . Most studies used the human H or L ferritin chains, which are able to self-assemble in different proportions to produce a variety of heteropolymers (Santambrogio et al., 1993; Rucker et al., 1997) . This allows the possibility to decorate ferritin surface with multiple functionalities through genetic and chemical modification to achieve desired properties for therapeutic and/or diagnostic purposes (Jeon et al., 2013) . In particular, it can be used as peptide carrier that can target specific receptors.
In the present study, we describe an approach to produce and purify a chimeric HepcH fusion protein that can be renatured onto a stable 24-mer ferritin shell when co-assembled together with human H-and L-chains. In addition, we demonstrate that the resulting assembled hybrid HepcH-FTH or -FTL is able to target the iron exporter ferroportin inducing its cellular internalization.
Materials and methods

Plasmid construction
The construct that overproduces HepcH monomer in E. coli was done in the pASK-IBA43plus vector (IBA, BioTAGnology). The first step was the insertion of the full human FTH cDNA, amplified by PCR using the primers NheI hFTH F/BamHI hFTH R (Table S1 , Supplementary data are available at PEDS online), in the NheI and BamHI sites. The second step was the insertion of camel hepcidin coding region cDNA, amplified by PCR using the primers NheI H25 F/NheI H25 R (Table S1 , Supplementary data are available at PEDS online), in the NheI site at the 5'end of huFTH sequence. The construct was verified by DNA sequencing, using the primers pASK F/pASK R (Table S1 , Supplementary data are available at PEDS online), which confirmed that the sequence of camel hepcidinhuman ferritin H-chain was correct.
Expression and solubilization of HepcH monomer
Human ferritin H-chain fused directly downstream the mature camel hepcidin was cloned into the pASK-43 plus vector and expressed using BL21 (DE3) pLys E. coli strain. Growth of the transformed E. coli was done in 1 L LB medium (10 g Tryptone, 5 g Yeast extract, 5 g NaCl), with 100 µg/mL ampicillin, at 37°C, for 1-2 h until the culture reached an optical density (OD 600 ) of 0.5. Then the expression was induced by the addition of anhydrotetracycline with a final concentration of 200 µg/L, for 4 h. Cells were harvested by centrifugation at 7000 RPM for 10 min. The pellet was washed twice in Tris-HCl 20 mM pH 7.4 and sonicated for cytoplasmic protein extraction. The sonicate pellet was then collected at 12 000 RPM and washed twice in Tris 20 mM, 2 M Urea, 0.1% Triton X100, pH 7.4. The insoluble HepcH monomer was solubilized with a weight to volume ratio of 1:1 in 6 M Guanidine hydrochloride (GdnHCl) pH 4.7 and incubated with stirring for 18 h at 4°C. The suspension was sonicated to homogenize the solution.
HepcH construct is expressed in association with iron
Iron content in HepcH construct was determined by ferrozine assay. Briefly, the solubilized HepcH construct (4.5 μM) was incubated with 1 mM TCEP (Tris(2-carboxyethyl)phosphine hydrochloride, Sigma) in the presence of an excess of ferrozine (3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate, Sigma) in 50 mM Tris-HCl buffer pH 7.0. ). In parallel, a control containing HepcH construct (4.5 μM) and ferrozine, in absence of TCEP, was also monitored at 562 nm. Absorbance measurements were recorded using a Cary 50 Bio UV-vis spectrophotometer.
Thiol quantification
Thiol quantification of HepcH monomer was done using Ellman's method (Ellman, 1959) . Briefly, the solubilized HepcH monomer (0.12 mg/mL, 5 μM) was first fully reduced by incubation with a molar excess of TCEP (tris(2-carboxyethyl)phosphine, Sigma) at 4°C. After 1 h of incubation, the pH was lowered to 3.5-4 by dropwise addition of 0.1 N HCl to inhibit disulfide bond formation, and the excess of unreacted TCEP was removed by successive dialysis steps at pH 4 using a 12 kDa dialysis membrane (Sigma). Free sulfhydryl quantification was then performed by incubation for 1 h at room temperature with an excess of DTNB (5,5′-dithio-bis-(2-nitrobenzoic acid), Sigma) at a final concentration of 500 µM in a reaction buffer containing 0.1 M sodium phosphate, 1 mM EDTA at pH 8. The total concentration of free thiol groups was measured spectrophotometrically at 412 nm using a value of 14 150 M −1 cm −1 for the molar extinction coefficient of TNB 2-. For free sulfhydryl-group detection in the final renatured HepcH-FTH and HepcH-FTL samples, we used the protocol described above without the reductive step with TCEP.
Assembly of HepcH-FT heteropolymers
Assembly of HepcH in an heteropolymeric molecule was performed by adding denatured FTH or FTL before renaturation, followed by 10-fold dilution in buffer. Prior to the refolding, the HepcH monomer was made iron-free following the protocol described by Levi et al. with slight modifications (Levi et al., 1988) . Briefly, solubilized HepcH monomer in 6 M GdnHCl was incubated with 1% thioglycolic acid, pH 5.5, and 2,2-bipyridyle followed by 48 h extensive dialysis against 6 M GdnHCl, pH 7.0. Once iron-free, the resulting clear colorless and unfolded HepcH sample was incubated with different ratios of FTH or FTL denatured in 6 M or 8 M GdnHCl respectively, at pH 3.5, using different HepcH/FT molar ratios (5:1; 1:1; 1:2; 1:5; 1:11). The mixture was then refolded by at least 10-fold dilution into 0.1 M Tris-HCl buffer pH 7.4, 2 mM TCEP, and then incubated at 4°C for 1-2 days. The resulting solution was then clarified by centrifugation at 4000 RPM for 15 min, concentrated 10-fold using a 100 kDa molecular weight cut-off centrifugal filter (Millipore, Billerica, Massachusetts) and analyzed in 7% nondenaturing PAGE. Cysteine oxidation for the final refolded HepcH-FTH and HepcH-FTL heteropolymers renatured in the proportions 1:2; 1:5 and 1:11, was carried out using the glutathione redox system (GSH/GSSG) as described by Jordan et al. (2009) . Briefly, the refolded hybrid ferritin samples containing HepcH construct were dialyzed for 48 h at 4°C using a 12 kDa dialysis membrane (Sigma) against a buffer containing 0.1 M Tris pH 8 and 0.4 mM GSH/ 0.4 mM GSSG in order to slowly oxidize cysteine thiols in parallel with gradual removal of the TCEP, enhancing thus the intramolecular S-S formation. Then the sample was thoroughly dialyzed at room temperature against 20 mM Tris-HCl pH 7.4 to remove the GSG/GSSG redox system and the resulting oxidized HepcH-FTH and -FTL were run on a native 7% PAGE. Sample concentration was measured with Bradford assay (Biorad) using BSA as a control.
Western blot analysis
Samples of 30 μg of protein were loaded on 12% SDS-PAGE or 7% non-denaturing PAGE and then blotted onto Amersham western blotting membrane (GE Healthcare, Life Sciences) with monoclonal anti-human FTH and FTL (Sigma Aldrich) and polyclonal antihepcidin (Rabbit anti-hepcidin-25, Abcam) antibodies for SDS-PAGE. For non-denaturating PAGE, monoclonal antibodies rH02 and LF03, prepared against human ferritin H-and L-chains respectively, were used as previously described (Luzzago et al., 1986; Cozzi et al., 1989) . Briefly, the membrane was blocked with 2% defatted milk in TBS-T for 30 min at 37°C under agitation and then incubated with anti-human FTH or FTL (1:1000) and anti-hepcidin (1:1000) primary antibodies during 1-2 h at 37°C or overnight at 4°C. After washing three times with TBS-T, the membrane was incubated for 1 h at 37°C with the secondary anti-mouse (1:20 000) and then with anti-rabbit (1:15 000) antibodies conjugated with peroxidase (anti-mouse immunoglobulin G, Dako or anti-rabbit immunoglobulin G, BioFX Laboratories). After washing three times at room temperature the signal was revealed by enhanced chemiluminescence (ECL) kit (GE, Healthcare) and recorded with KODAK Image Station 440CF (Kodak).
Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF)/TOF mass spectrometry (MS) [MALDI-TOF/TOF-MS] analysis
MALDI-TOF/TOF-MS analysis was performed on AB Sciex 5800 MALDI-TOF/TOF-MS as described by Gianoncelli and coworkers (Gianoncelli et al., 2015) .
Cellular studies
Mouse monocyte-macrophage cell line J774 (Lombardy and Emilia Romagna Experimental Zootechnic Institute) was cultured as previously described (Delaby et al., 2005) . Briefly, cells were grown in DMEM (PAA Laboratories GmbH), 10% endotoxin-free fetal bovine serum (Euroclone), 0.04 mg/mL gentamicin (Euroclone), 2 mM L-glutamine (PAA Laboratories GmbH), and maintained at 37°C in 5% CO 2 . Cells (200 000 cells/well) were seeded onto 12-well plates, and after 24 h were grown for 12 h in presence of 100 µM ferric ammonium citrate (FAC) to induce ferroportin expression. The day after, cells were incubated with the hybrid ferritin heteropolymers containing different ratio of HepcH:FTH at a final concentrations of 0.2 µM (1:5) and 0.2 µM (1:11) and HepcH: FTL at a final concentrations of 0.1 µM (1:5) and 0.2 µM (1:11). The controls were cells without FAC treatment and the native FTH and FTL homopolymers at the same concentrations. Experiments were done at 37°C for 15, 30, 60 and 120 min. After this time, the supernatant was discarded and the cells washed with cold PBS and lysed using cold buffer (200 mM Tris-HCl at pH 8, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 10% glycerol, 1 mM sodium fluoride, 1 mM sodium orthovanadate, Protease Inhibitor Cocktail; Roche). Protein content was determined by colorimetric BCA assay (bicinchoninic acid assay, Pierce) and 20 µg of total proteins were separated by native polyacrylamide gel electrophoresis and Western Blotting was performed using polyclonal anti-rabbit ferroportin, anti-human FTH (RH02) and FTL (LF03) antibodies for the detection of proteins internalized by the cells.
Results
Chimeric construct for HepcH expression
The HepcH plasmid construct encoding the sequence of the mature camel hepcidin fused to that of the human H ferritin (huFTH) is shown in Fig. 1A . In the ferritin shell the N-terminus of the subunits is exposed, thus the fused hepcidin is expected to be accessible and available for ferroportin binding. The HepcH monomer of 213 amino acids (Fig. 1A and Table I ) was efficiently expressed by the transformed E. coli and it had the expected molecular size of 24 kDa on SDS-PAGE (Fig. 1B) . In immunoblotting experiments, the HepcH monomer was recognized by antibodies specific for human FTH and for hepcidin-25, which also recognized the recombinant FTH and the commercial human Hepcidin-25, respectively (Fig. 1C) . In MALDI-TOF mass spectrometry, HepcH monomer solubilized in 6 M GdnHCl pH 4.7, exhibited a peak at m/z 24 339.55 corresponding to the theoretical average mass of 24 410.50 ( Fig. 1D and Table I ). The peak at m/z 48 466.0313 corresponds to HepcH dimer (Fig. 1D ).
The insoluble HepcH is expressed in association with iron
The insoluble fractions of the homogenate of cell expressing HepcH subunit showed a distinct reddish color not present in those expressing huFTH ( Fig. 2A) . Treatments of the precipitates with 6 M urea at pH 4.5-5.0 solubilized the recombinant protein together with the color (Fig. 2A) . The UV/vis absorption spectra of solubilized HepcH subunit showed a major peak at 280 nm and a shoulder around 420 nm (Fig. 2B , black line) not present in ferritin H-chain (Fig. 2B , gray line) that decreased after reduction with 100 mM dithionite (Fig. 2B, dashed line) . A similar behavior was described for a FTHHepcidin chimera expressed in E. coli in association with iron (Gerardi et al., 2005) . The iron bound to HepcH was quantified amounts by chelation with ferrozine. The solubilized preparation was incubated with ferrozine and an agent (TCEP) to reduce iron, and the formation of the ([Fe II (fz) 3 ]) complex was followed by its absorbance at 562 nm. The colorimetric reaction started immediately after addition of TCEP and reached a plateau after 24 h (Fig. 2C) . In the absence of reducing agent, the color development was negligible (Fig. 2D) indicating that the bound iron is the Fe(III) form. We calculated a value of~19 µM of iron in the complex, corresponding to about 4.1 Fe atoms per HepcH monomer, as isolated.
Quantification of free sulfhydryl groups in the solubilized HepcH FTH has 3 Cys and hepcidin has 8, thus the detection of the free thiols was of interest. The purified HepcH peptide was subjected to Ellman's assay. The absorbance spectra of HepcH incubated with 500 µM of DTNB before and after reduction of the thiols are shown in Fig. S1 , Supplementary data are available at PEDS online. We calculated~38.7 µM of sulfhydryl groups in the HepcH sample after full reduction corresponding to about 7.7 free sulfhydryl per HepcH monomer (Fig. S1 , bars, Supplementary data are available at PEDS online). This indicates that all the thiols are not accessible under non-reducing conditions, and that after reduction about 8 out of 11 become accessible, confirming the presence of the hepcidin extension in the purified HepcH construct.
Assembly, oxidation and characterization of HepcH-FTH and HepcH-FTL heteropolymers
Initial experiments to renature HepcH by diluting the denatured peptide into the renaturing buffers as in (Santambrogio et al., 1993) were unsuccessful, indicating that the N-terminal hepcidin interferes with folding or assembly. Thus, we tried the co-renaturation together with H-or L-chains, on the basis of previous evidence that coassembly facilitates the folding of altered ferritin chains (Levi et al., 1994) . We set up a series of experiments in which the denatured and reduced HepcH was firstly mixed with denatured FTH or FTL at different ratios, and then refolded by 10-fold dilution in buffer to test the formation of stable ferritin shells. We obtained heteropolymeric ferritins composed of HepcH and FTH or FTL only when mixed in the proportions 1:11; 1:5 and in a less extent in 1:2. The assembled ferritin shells produced a single discrete band in 8% non-denaturing PAGE, the mobility of which decreased with the increase of HepcH, an indirect support that the hepcidin moiety is exposed and slows the mobility ( Fig. 3A and B) . When the refolding was done with higher proportions of HepcH:FT (1:1, 2:1 and 5:1), the product showed a large smear on PAGE indicating the formation of disordered and poorly structured molecules (Fig. 3A) . Immunoblotting with antihuman FTH and anti-hepcidin antibodies, confirmed the presence of HepcH construct assembled in ferritin shells (Fig. 3C) . A schematic representation of the renatured HepcH-FT hybrid heteropolymer is shown in the Fig. 3D . Renaturation of the hybrid ferritins was done under reducing conditions, and thus needed the re-oxidation of the hepcidin cysteines to form the four disulfide bridges present in hepcidin structure. For this reason, the hybrid ferritins were incubated with the glutathione redox system at pH 8 to promote formation of thiosulfate anions, which represent the reactive species during disulfide formation. The redox pair consisted of reduced and oxidized glutathione at concentrations of 0.4 mM each, followed by extensive dialysis. The final oxidized heteropolymeric HepcH-FTH and HepcH-FTL showed the typical ferritin monomer and oligomers ladder pattern in PAGE ( Fig. 4A ) and no free thiols could be detected by Ellman's reaction testifying the full oxidation of the eight cysteine residues constituting the camel hepcidin (Fig. 4B, bars Table I ). The differences between the theoretical and experimental masses is due to the instrument settings that for mid/high MW uses only one time of flight and has low resolution with deviations up to 100 Da.
The HepcH-FTH heteropolymers bind macrophagic cells and cause ferroportin degradation
The major hepcidin function is to bind ferroportin exposed to cellular plasma membrane an activity that we expected could be monitored by taking advantage of the ferritin bound to it. To verify this, we incubated the mouse macrophage J774 cell with 100 µM FAC to induce ferroportin expression, the cells were incubated with the heteropolymers using FTH and FTL homopolymers as controls. Immunoblotting with anti-ferritin antibodies showed that HepcH-FTH and FTL were strongly retained by the cells after 2 h of incubation using the molar ratio HepcH/FT of 1:5 ( Fig. 5A and B) . However, 15-30 min of cell treatment was insufficient for the binding of this ferritins on the macrophage cell surface (data not shown). Moreover, the FTH and FTL homopolymers were retained only in trace amounts after 2 h of incubation ( Fig. 5A and B) . Interestingly, the intensity of the binding increased with the increase of the proportion of HepcH in the heteropolymers, both with FTH and FTL ( Fig. 5A and B, ratio 1:5 versus 1:11). This indicates that the binding can be safely attributed to the exposed hepcidin moiety that likely interacts with ferroportin. After binding, the hepcidin role is to induce ferroportin degradation, therefore to verify this we analyzed the ferroportin content of the treated cells by western blotting using anti-ferroportin antibodies. Figure 5C shows that the recombinant heteropolymer HepcH-FTH induced a degradation of ferroportin similar to that by treatment with synthetic hepcidin and higher than untreated cells and cells treated with native ferritin.
Discussion
The production of a functional hepcidin attached to a large multimeric protein like ferritin may be useful to follow hepcidin binding to ferroportin and analyze its functionality. In a previous approach, we fused the hepcidin moiety at the C-terminus of ferritin, but the hepcidin was buried inside the cavity and thus not functional (Gerardi et al., 2005) . Here we succeed to fuse at the N-terminus of the ferritin H-chain a camel hepcidin, which differs from the human one in only 2 residues and is similarly functional and more stable (Boumaiza et al., 2014 (Boumaiza et al., , 2015 . This strategy was expected to display the Nterminal domain of hepcidin exposed and available to the interaction with ferroportin (Nemeth et al., 2005; Preza et al., 2011) . The HepcH construct was efficiently expressed in E. coli as insoluble reddish aggregate rich in iron. The approaches to renature the construct were unsuccessful, indicating that the hepcidin moiety interferes with the process of ferritin folding and assembly. This did not occur when hepcidin was fused at the C-terminus and formed soluble and stable ferritin shells (Gerardi et al., 2005) . A common property of the two chimeric constructs is the binding of iron during expression in E. coli, which in the present study was calculated to be about 4 iron atoms per hepcidin molecule. The spectroscopic characteristics of the HepcH construct as isolated were reminiscent to the ones of Fe/S clusters. Its UV/vis spectrum showed a broad shoulder at 420 nm, which was absent in the wild-type ferritin. This is very likely due to the Cys dense sequence of hepcidin that may form active iron binding sites under low potential conditions. In fact, we found that the thiols of these Cys were not available if not treated with reducing agents. The insolubility of the HepcH was initially attributed to the Cys-iron complexes, but also the approaches to renature it under reducing conditions failed, indicating that the hepcidin moiety interferes with the folding/assembly. To solve this problem, we took advantage of the capacity of ferritin subunits to co/assemble together and facilitate their folding. For example, an insoluble L-chain with ferroxidase activity was induced to fold and assemble together with wild-type Lchain (Levi et al., 1994) . This approach worked also in this situation and we obtained heteropolymers of HepcH with both the H-and Lchains. We tried different HepcH:FTH and HepcH:FTL molar ratios, and we obtained a maximum number of about 4 HepcH subunits per shell (ratio 1:5). When HepcH was in excess, the renaturation was not successful. The ferritins so obtained retained all the characteristics of hybrid molecules, including the electrophoretic mobility and the recognition by antibodies for the two moieties, ferritin and hepcidin. Of interest is that disulfide bridges are not involved in wildtype ferritin stability, and thus the hybrid ferritin shells could be treated with glutathione redox system to allow the proper formation of the hepcidin disulfides bonds. This was apparently successful, since after the treatments no thiol group was accessible to Ellman's reagent, and, more important, the heteropolymers was able to bind J774 cells exposing ferroportin. The specificity of the binding to the cells was indicated by the evidence that it occurred only with the HepcH-containing molecules and that its strength was related to the HepcH content. A minor binding was found with FTH homopolymers, probably due to the expression of the H-ferritin receptor TIM-2 in these cells (Han et al., 2011) , while the binding of the FTL homopolymer was negligible. Hepcidin exerts it function by binding and then inducing ferroportin degradation, and in fact we observed that after 2 h incubation with HepcH-FTH the level of ferroportin in the J774 cells decreased, as it occurred in the cells treated with the synthetic hepcidin, while the incubation with FTH had no evident effect. This indicates that heteropolymer is biologically functional.
In conclusion, present data show a genetic approach to produce hepcidin displayed on ferritin surface. Fusion hepcidin-ferritin H subunit assembled together with H-or L-chains at a ratio of 1:5, produced a stable and functional 24-mer ferritin exposing about 4 hepcidin per shell. The evidence that this molecule specifically binds cells that express high levels of ferroportin indicates that it might be an interesting tool to study more in detail the mechanism of interaction of hepcidin and ferroportin and how the complex is degraded. It might also be used as an alternative approach for the development of new concepts and prodrugs of anticancer drug-vectorization using the specific hepcidin-ferroportin cell internalization pathway.
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Abbreviations
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